CenterWatch

Clinical Trial Details

Overview

Research Study Summary

Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

Purpose

To compare the efficacy of once daily injections in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy

Patient Inclusion Criteria:

  • Cancer patients with metastatic or locally advance solid tumor of the lung, pancreas, stomach, colon/rectum, bladder or ovary, planned to start a new course of chemotherapy with a minimum intent of 3 months therapy

Patient Exclusion Criteria:

  • Life expectancy of less than 3 months, any major surgery within the last 4 weeks or planned during the study treatment period, any treatment with other anti-thrombotic agents within 2 weeks prior to randomization

To Learn more

CW ID:163091
Date Last Changed: July 24, 2013

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Facility Type
N/A

Contact

Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Phone: 701-751-1128
Fax: 701-751-1131

View Map

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.